Monte Rosa Therapeutics Inc
NASDAQ:GLUE
Income Statement
Earnings Waterfall
Monte Rosa Therapeutics Inc
Income Statement
Monte Rosa Therapeutics Inc
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
6
+441%
|
15
+160%
|
76
+405%
|
159
+111%
|
178
+12%
|
182
+2%
|
|
| Operating Income | |||||||||||||||||||||
| Operating Expenses |
(28)
|
(35)
|
(48)
|
(61)
|
(73)
|
(86)
|
(95)
|
(103)
|
(112)
|
(122)
|
(132)
|
(141)
|
(143)
|
(145)
|
(145)
|
(144)
|
(157)
|
(162)
|
(163)
|
(173)
|
|
| Selling, General & Administrative |
(4)
|
(6)
|
(9)
|
(13)
|
(16)
|
(20)
|
(23)
|
(30)
|
(35)
|
(40)
|
(42)
|
(38)
|
(40)
|
(34)
|
(35)
|
(34)
|
(44)
|
(35)
|
(34)
|
(35)
|
|
| Research & Development |
(24)
|
(29)
|
(39)
|
(49)
|
(57)
|
(66)
|
(72)
|
(78)
|
(77)
|
(94)
|
(102)
|
(109)
|
(103)
|
(112)
|
(111)
|
(110)
|
(113)
|
(127)
|
(129)
|
(138)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
5
|
0
|
11
|
11
|
6
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(28)
N/A
|
(35)
-26%
|
(48)
-36%
|
(61)
-28%
|
(73)
-19%
|
(86)
-18%
|
(95)
-11%
|
(103)
-9%
|
(112)
-9%
|
(122)
-9%
|
(132)
-8%
|
(141)
-7%
|
(143)
-2%
|
(144)
0%
|
(139)
+3%
|
(129)
+7%
|
(81)
+37%
|
(2)
+97%
|
15
N/A
|
9
-43%
|
|
| Pre-Tax Income | |||||||||||||||||||||
| Interest Income Expense |
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
1
|
2
|
4
|
6
|
7
|
8
|
8
|
9
|
9
|
10
|
11
|
12
|
13
|
13
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(8)
|
(9)
|
(9)
|
(9)
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(36)
N/A
|
(44)
-22%
|
(57)
-30%
|
(70)
-23%
|
(74)
-5%
|
(86)
-16%
|
(94)
-9%
|
(101)
-8%
|
(109)
-7%
|
(117)
-7%
|
(125)
-7%
|
(133)
-6%
|
(135)
-2%
|
(135)
+0%
|
(130)
+4%
|
(119)
+8%
|
(70)
+41%
|
9
N/A
|
28
+200%
|
22
-23%
|
|
| Net Income | |||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(3)
|
(3)
|
(4)
|
(1)
|
|
| Income from Continuing Operations |
(36)
|
(44)
|
(57)
|
(70)
|
(74)
|
(86)
|
(94)
|
(101)
|
(109)
|
(117)
|
(125)
|
(133)
|
(135)
|
(135)
|
(130)
|
(119)
|
(73)
|
6
|
24
|
21
|
|
| Net Income (Common) |
(36)
N/A
|
(44)
-22%
|
(57)
-30%
|
(70)
-23%
|
(74)
-5%
|
(86)
-16%
|
(94)
-9%
|
(101)
-8%
|
(109)
-7%
|
(117)
-7%
|
(125)
-7%
|
(133)
-6%
|
(135)
-2%
|
(135)
+0%
|
(130)
+4%
|
(119)
+8%
|
(73)
+39%
|
6
N/A
|
24
+293%
|
21
-13%
|
|
| EPS (Diluted) |
-0.81
N/A
|
-0.99
-22%
|
-1.28
-29%
|
-1.52
-19%
|
-1.59
-5%
|
-1.85
-16%
|
-2.01
-9%
|
-2.16
-7%
|
-2.3
-6%
|
-2.36
-3%
|
-2.53
-7%
|
-2.66
-5%
|
-2.63
+1%
|
-2.24
+15%
|
-1.83
+18%
|
-1.45
+21%
|
-0.98
+32%
|
0.07
N/A
|
0.29
+314%
|
0.25
-14%
|
|